These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6773532)

  • 1. Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
    Miettinen TA; Huttunen JK; Ehnholm C; Kumlin T; Mattila S; Naukkarinen V
    Atherosclerosis; 1980 Jun; 36(2):249-59. PubMed ID: 6773532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins.
    Atmeh RF; Stewart JM; Boag DE; Packard CJ; Lorimer AR; Shepherd J
    J Lipid Res; 1983 May; 24(5):588-95. PubMed ID: 6875383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrate.
    Brook JG; Lavy A; Aviram M; Zinder O
    Atherosclerosis; 1980 Aug; 36(4):461-9. PubMed ID: 7417365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term use of probucol in the multifactorial primary prevention of vascular disease.
    Miettinen TA; Huttunen JK; Naukkarinen V; Strandberg T; Vanhanen H
    Am J Cardiol; 1986 Jun; 57(16):49H-54H. PubMed ID: 2873740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations.
    Nestel PJ; Hunt D; Wahlqvist ML
    Atherosclerosis; 1980 Dec; 37(4):625-9. PubMed ID: 7459005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
    Sale JK; Johnstone JH
    Ann Clin Biochem; 1981 Mar; 18 (Pt 2)():71-5. PubMed ID: 7259072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Mordasini R; Riesen W; Oster P; Keller M; Middelhoff G; Lang PD
    Atherosclerosis; 1981 Oct; 40(2):153-8. PubMed ID: 6796096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in rat serum lipids and apolipoproteins following clofibrate treatment.
    Dashti N; Ontko JA
    Atherosclerosis; 1983 Dec; 49(3):255-66. PubMed ID: 6419747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma carnitine and lipid-lowering drugs.
    Nestruck AC; Pande SV; Davignon J
    Atherosclerosis; 1985 Jun; 55(3):353-6. PubMed ID: 4015753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase.
    Miettinen TA; Huttunen JK; Kuusi T; Kumlin T; Mattila S; Naukkarinen V; Strandberg T
    Clin Chim Acta; 1981 Jun; 113(1):59-64. PubMed ID: 6786808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of probucol on serum lipoprotein and apoprotein profiles in renal transplant patients.
    Okubo M; Horii A; Kamata K; Takeuchi Y; Tsukamoto Y; Kobayashi N; Sato K; Kumano K; Endo T
    Am J Kidney Dis; 1998 Feb; 31(2):356-9. PubMed ID: 9469511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between the HDL apoproteins and AI isoproteins in subjects with the AIMilano abnormality.
    Franceschini G; Sirtori M; Gianfranceschi G; Sirtori CR
    Metabolism; 1981 May; 30(5):502-9. PubMed ID: 6785551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns.
    Franceschini G; Sirtori CR; Bosisio E; Gualandri V; Orsini GB; Mogavero AM; Capurso A
    Atherosclerosis; 1985 Dec; 58(1-3):159-74. PubMed ID: 3937534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of clofibrate, bile-sequestering agents and probucol on high-density lipoprotein levels.
    Glueck C
    Am J Cardiol; 1983 Aug; 52(4):28B-30B. PubMed ID: 6577781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.